Some researchers warn this new class of drugs may promote liver problems, cancer, and health problems associated with cholesterol- and sulfate-deficiency.
Results from a 78-week long study shows the PCSK9 inhibitor alirocumab (Praluent) causes higher incidence of many of the same side effects as statins.
PCSK9 inhibitors stand poised to wreak great havoc in those who take it. It’s also worth noting that the effects on cardiovascular morbidity and mortality have not yet been determined for these drugs.
This means: not fully tested yet worse than statins.
Why is it released prematurely then? Potential of big money. Surprised?
Read the rest of the article here: FDA Approves Potentially Disastrous Cholesterol-Lowering Drug